BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malas TB, Leonhard WN, Bange H, Granchi Z, Hettne KM, Van Westen GJP, Price LS, 't Hoen PAC, Peters DJM. Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles. EBioMedicine 2020;51:102585. [PMID: 31879244 DOI: 10.1016/j.ebiom.2019.11.046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Endocannabinoid System in Polycystic Kidney Disease. Am J Nephrol 2022;53:264-72. [PMID: 35263737 DOI: 10.1159/000522113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Pagliarini R, Podrini C. Metabolic Reprogramming and Reconstruction: Integration of Experimental and Computational Studies to Set the Path Forward in ADPKD. Front Med (Lausanne) 2021;8:740087. [PMID: 34901057 DOI: 10.3389/fmed.2021.740087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Muñoz JJ, Anauate AC, Amaral AG, Ferreira FM, Watanabe EH, Meca R, Ormanji MS, Boim MA, Onuchic LF, Heilberg IP. Ppia is the most stable housekeeping gene for qRT-PCR normalization in kidneys of three Pkd1-deficient mouse models. Sci Rep 2021;11:19798. [PMID: 34611276 DOI: 10.1038/s41598-021-99366-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
4 Mao Z, Valluru MK, Ong ACM. Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone. Clin Kidney J 2021;14:1715-8. [PMID: 34221378 DOI: 10.1093/ckj/sfab062] [Reference Citation Analysis]
5 Gimpel C, Bergmann C, Mekahli D. The wind of change in the management of autosomal dominant polycystic kidney disease in childhood. Pediatr Nephrol 2021. [PMID: 33677691 DOI: 10.1007/s00467-021-04974-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
6 Saini AK, Saini R, Singh S. Autosomal dominant polycystic kidney disease and pioglitazone for its therapy: a comprehensive review with an emphasis on the molecular pathogenesis and pharmacological aspects. Mol Med 2020;26:128. [PMID: 33308138 DOI: 10.1186/s10020-020-00246-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kiseleva AA, Golemis EA. Informatics-guided drug repurposing for Autosomal Dominant Polycystic Kidney Disease (ADPKD). EBioMedicine 2020;52:102628. [DOI: 10.1016/j.ebiom.2020.102628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]